The treatment of MS with the anti-CD25 (IL-2Rα) monoclonal antibody daclizumab identified the expansion of immunoregulatory CD56bright NK cells and the latter effectively blocked disease activity (30, 34, 35). The gene discussed is IL2RA; the disease is myeloid sarcoma.